Forge Therapeutics recently took in more funding — up to $11.1 million — to battle life-threatening infections called “superbugs.”
Under a new law, California public companies must have at least one woman on their board by the end of 2019. It appears the biggest impact will be in San Diego.
At the annual J.P. Morgan Healthcare conference, major San Diego players like Illumina naturally command attention. But quietly, Mirati Therapeutics had a strong showing.
Earlier this month San Diego-based Retrophin’s board appointed a new president and CEO: Eric Dube.
PHARMA: Co. Confident in Revenue, Cash and Portfolio
Ligand Pharmaceutical’s stock has lost more than half of its value since October, puzzling the company and most analysts, though a vocal minority are skeptical of the company’s pipeline.
Jan Caldwell, who has sat on Scripps Health’s board since 2012, was named board chairman, it was announced Jan. 14.
Liver drug developer Cirius Therapeutics on Jan. 11 put in a prospectus for an $86 million initial public offering.
UC San Diego Health has opened a new senior emergency department, complete with a team trained in geriatric medicine and senior-friendly architectural design.
The federal government shutdown has stalled San Diego biotechs knocking on the door of an initial public offering.
The Salk Institute’s board recently voted to give President Rusty Gage a five-year job extension.
Poseida Therapeutics on Jan. 4 filed for an initial public offering, seeking to raise $115 million.
San Diego’s biotech industry took a beating as part of a larger fourth quarter stock retreat.
San Diego medtech NuVasive cut two vice president positions and shifted the responsibilities of other management as part of a reorganization that the company announced Jan. 3.
Roswell Biotechnologies has taken in a $32 million series A round in a bid to bring down the cost of DNA sequencing through what the company calls a molecular electronics platform.
San Diego-based Ligand Pharmaceuticals will pay $10 million to Palvella Therapeutics under a recent deal.